Chagas Disease
Also known as: American trypanosomiasis, South American trypanosomiasis
Methodology & AI Transparency ⓘ
Chagas Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Chagas disease? Chagas disease, or American trypanosomiasis, is an illness that can cause serious heart and stomach problems.
- 2 Real-world patient consensus: Clinical coding for Chagas Disease uses ICD-10 B57.2 across Heart & Vascular specialty care.
- 3 Typical cash cost range: Workup highlights for Chagas Disease (B57.2): ambulatory rhythm monitoring [Chagas Disease B57.2].
- 4 Top reported side effects / signs: Longitudinal Chagas Disease monitoring tracks Left Ventricular Ejection in Chagas Disease (B57.2: Fraction (LVEF)) toward 55% – 70% (B57.2).
Ask our AI Specialists anything about Chagas Disease
What Is Chagas Disease?
What is Chagas disease? Chagas disease, or American trypanosomiasis, is an illness that can cause serious heart and stomach problems. It is caused by a parasite . Chagas disease is common in Latin America, especially in poor, rural areas. It can also be found in the United States, most often in people who were infected before they moved to the U.S. What causes Chagas disease? Chagas disease is caused by the Trypanosoma cruzi parasite. It is usually spread by infected blood-sucking bugs called triatomine bugs. They are also known as "kissing bugs" because they often bite people's faces. When one of these bugs bites you, it leaves behind infected waste.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Chagas Disease (B57.2) center on coronary microvascular remodeling [Chagas Disease B57.2]. Cross-referenced with NIH MeSH (Chagas Disease), targeted heart & vascular interventions aim to normalize Left Ventricular Ejection in Chagas Disease (B57.2: Fraction (LVEF)).
Common Symptoms & Clinical Signs
- • Live in rural areas of Latin America
- • Have seen the bugs, especially in those areas
- • Presentation of Chagas Disease (B57.2): palpitations, skipped beats, in Chagas Disease (B57.2: or irregular resting)
- • Secondary Chagas Disease clinical sign: unexplained lower-extremity ankle in Chagas Disease (B57.2: edema or rapid)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Chagas Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B57.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Chagas Disease (B57.2: Fraction (LVEF)) | 55% – 70% (B57.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Chagas Disease B57.2] | < 100 pg/mL (B57.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Chagas Disease B57.2] | < 14 ng/L (B57.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chagas Disease
Treatment selection for Chagas Disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chagas Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in The results demonstrate a serological response to treatment with nifurtimox measured by the ELISA F29 test in children diagnosed with Chagas disease. PLoS neglected tropical diseases • 2023-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37352322 ↗ |
| New Insights on Phenomapping-derived selection of fractional flow reserve or optical coherence: What a 405-Participant Study Found Compared with a functional assessment, an OCT-based approach reduces revascularisation in patients with STEMI/NSTEMI, while FFR proved non-inferior for patients with stable angina. Open heart • 2025-09-17 • Phase III Randomized Trial | N = 405 | 87/100 | PMID 40967674 ↗ |
| Can This Approach Help? Inside the Latest Research on Identification of serum soluble ST2 receptor as a novel heart failure Serum soluble ST2 is a novel biomarker for neurohormonal activation in patients with heart failure. Circulation • 2003-02-11 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 12578875 ↗ |
Chagas Disease Patient Community & “People Like Me” Threads
Filter Chagas Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.